Geron Presents New Data That Document Progress In Development Of Theraputic Products From Human Embryonic Stem Cells

Geron announced the presentation of new data that document the company’s progress in the development of first-in-class therapeutic products from human embryonic stem cells (hESCs) for the treatment of degenerative diseases. The data pertained to four products in development: (1) GRNOPC1, Oligodendroglial Progenitor Cells for acute spinal cord injury, (2) GRNIC1, Islet Clusters for diabetes, (3) GRNCM1, Cardiomyocytes for myocardial infarction and (4) osteoprogenitor cells for bone fractures and osteoporosis. Other presentations at the meeting described advances in hESC culture and derivation techniques and further characterization of hESC-derived hepatocytes for liver failure and drug metabolism testing.